{"organizations": [], "uuid": "ce2fdfd69dd64fd839e06b8662d043022699d541", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-gsk-to-transfer-rare-disease-gene/brief-gsk-to-transfer-rare-disease-gene-therapy-portfolio-to-orchard-therapeutics-idUSFWN1RP05B", "country": "US", "domain_rank": 408, "title": "BRIEF-GSK To Transfer Rare Disease Gene Therapy Portfolio To Orchard Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T10:04:00.000+03:00", "replies_count": 0, "uuid": "ce2fdfd69dd64fd839e06b8662d043022699d541"}, "author": "", "url": "https://www.reuters.com/article/brief-gsk-to-transfer-rare-disease-gene/brief-gsk-to-transfer-rare-disease-gene-therapy-portfolio-to-orchard-therapeutics-idUSFWN1RP05B", "ord_in_thread": 0, "title": "BRIEF-GSK To Transfer Rare Disease Gene Therapy Portfolio To Orchard Therapeutics", "locations": [], "entities": {"persons": [], "locations": [{"name": "ospedale san raffaele", "sentiment": "none"}], "organizations": [{"name": "orchard therapeutics reuters", "sentiment": "none"}, {"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 7:05 AM / in an hour BRIEF-GSK To Transfer Rare Disease Gene Therapy Portfolio To Orchard Therapeutics Reuters Staff \nApril 12 (Reuters) - GlaxoSmithKline PLC: \n* GSK SIGNS STRATEGIC AGREEMENT TO TRANSFER RARE DISEASE GENE THERAPY PORTFOLIO TO ORCHARD THERAPEUTICS \n* GSK TAKES 19.9 PCT EQUITY STAKE IN ORCHARD AND SEAT ON BOARD \n* GSK TO RECEIVE FINANCIAL CONSIDERATIONS IN FORM OF ROYALTIES AND COMMERCIAL MILESTONE PAYMENTS RELATED TO ACQUIRED PORTFOLIO \n* BOTH COS AGREED TO A TRANSITION PERIOD DURING WHICH GSK WILL CONTINUE TO CONDUCT CERTAIN ACTIVITIES THROUGH TO END OF 2018 \n* ORCHARD TO ASSUME OBLIGATIONS ARISING FROM GSK’S 2010 COLLABORATION AGREEMENT WITH OSPEDALE SAN RAFFAELE, FONDAZIONE TELETHON \n* ORCHARD TO ALSO ASSUME ALL OBLIGATIONS ARISING FROM GSK’S COLLABORATION AGREEMENT WITH MOLMED Further company coverage:", "external_links": [], "published": "2018-04-12T10:04:00.000+03:00", "crawled": "2018-04-12T10:25:27.009+03:00", "highlightTitle": ""}